AAAAAA
Results: 1-25/87
Authors:
CUTLER NR
SRAMEK JJ
Citation: Nr. Cutler et Jj. Sramek, THE ROLE OF BRIDGING STUDIES IN THE DEVELOPMENT OF CHOLINESTERASE-INHIBITORS FOR ALZHEIMERS-DISEASE, CNS drugs, 10(5), 1998, pp. 355-364
Authors:
FRACKIEWICZKOZIOL EJ
SRAMEK JJ
CUTLER NR
Citation: Ej. Frackiewiczkoziol et al., POTENTIAL FOR ADVERSE EVENTS IN PATIENTS WITH GENERALIZED ANXIETY DISORDER, The Annals of pharmacotherapy, 32(1), 1998, pp. 132-134
Authors:
CUTLER NR
SALAZAR DE
JHEE SS
FORD NF
FULMOR IE
FRANCIS C
SRAMEK JJ
Citation: Nr. Cutler et al., ASSESSMENT OF BLOOD-PRESSURE IN MILD-TO-MODERATE HYPERTENSIVE PATIENTS FOLLOWING DOUBLE-BLIND CROSSOVER ADMINISTRATION OF AVITRIPTAN, SUMATRIPTAN, OR PLACEBO, Annals of neurology, 44(3), 1998, pp. 226-226
Authors:
KRAMER MS
CUTLER N
FEIGHNER J
SHRIVASTAVA R
CARMAN J
SRAMEK JJ
REINES SA
LIU GH
SNAVELY D
WYATTKNOWLES E
HALE JJ
MILLS SG
MACCOSS M
SWAIN CJ
HARRISON T
HILL RG
HEFTI F
SCOLNICK EM
CASCIERI MA
CHICCHI GG
SADOWSKI S
WILLIAMS AR
HEWSON L
SMITH D
CARLSON EJ
HARGREAVES RJ
RUPNIAK NMJ
Citation: Ms. Kramer et al., DISTINCT MECHANISM FOR ANTIDEPRESSANT ACTIVITY BY BLOCKADE OF CENTRALSUBSTANCE-P RECEPTORS, Science, 281(5383), 1998, pp. 1640-1645
Authors:
CUTLER NR
SRAMEK JJ
Citation: Nr. Cutler et Jj. Sramek, EXPLORATORY STUDIES - IMPLICATIONS FOR DRUG DEVELOPMENT IN ALZHEIMERS-DISEASE, Revue neurologique, 154, 1998, pp. 131-136
Authors:
CUTLER NR
ANAND R
HARTMAN RD
MESSINA JC
SRAMEK JJ
JHEE SS
Citation: Nr. Cutler et al., REDUCING CHOLINERGIC SIDE-EFFECTS - A COMPARISON OF ANTIEMETIC THERAPIES IN ALZHEIMER PATIENTS RECEIVING RIVASTIGMINE, Naunyn-Schmiedeberg's archives of pharmacology, 358(1), 1998, pp. 35205-35205
Authors:
CUTLER NR
JHEE SS
CYRUS P
BIEBER F
TANPIENGCO P
SRAMEK JJ
GULANSKI B
Citation: Nr. Cutler et al., SAFETY AND TOLERABILITY OF METRIFONATE IN PATIENTS WITH ALZHEIMERS-DISEASE - RESULTS OF A MAXIMUM TOLERATED DOSE STUDY, Life sciences, 62(16), 1998, pp. 1433-1441
Authors:
CUTLER NR
SALAZAR DE
JHEE SS
FULMOR IE
FORD N
SMITH RA
SRAMEK JJ
Citation: Nr. Cutler et al., PHARMACOKINETICS AND PHARMACODYNAMICS OF AVITRIPTAN IN PATIENTS WITH MIGRAINE AFTER ORAL DOSING, Headache, 38(6), 1998, pp. 446-452
Authors:
JHEE SS
SALAZAR DE
FORD NF
FULMOR IE
SRAMEK JJ
CUTLER NR
Citation: Ss. Jhee et al., MONITORING OF ACUTE MIGRAINE ATTACKS - PLACEBO-RESPONSE AND SAFETY DATA, Headache, 38(1), 1998, pp. 35-38
Authors:
SALAZAR DE
JHEE SS
SRAMEK JJ
FULMOR IE
FORD NF
CUTLER NR
Citation: De. Salazar et al., EFFECTS OF AVITRIPTAN ON BLOOD-PRESSURE IN PATIENTS WITH CONTROLLED MILD-TO-MODERATE HYPERTENSION, Clinical pharmacology and therapeutics, 63(2), 1998, pp. 20-20
Authors:
CUTLER NR
CYRUS P
SRAMEK JJ
BIEBER F
TANPIENGCO P
GULANSKI B
Citation: Nr. Cutler et al., THE MAXIMUM TOLERATED DOSE (MTD) OF METRIFONATE IN ALZHEIMERS PATIENTS, Biological psychiatry, 43, 1998, pp. 156-156
Authors:
CUTLER NR
FRIDAY G
SRAMEK JJ
HASKELL L
KNUTSSON M
JHEE SS
MARTIN T
OHLMAN S
Citation: Nr. Cutler et al., NXX-066 IN PATIENTS WITH ALZHEIMERS-DISEASE - A BRIDGING STUDY, Biological psychiatry, 43, 1998, pp. 157-157
Authors:
CUTLER NR
POLINSKY RJ
SRAMEK JJ
ENZ A
JHEE SS
MANCIONE L
HOURANI J
ZOLNOUNI P
Citation: Nr. Cutler et al., DOSE-DEPENDENT CSF ACETYLCHOLINESTERASE INHIBITION BY SDZ-ENA-713 IN ALZHEIMERS-DISEASE, Acta neurologica Scandinavica, 97(4), 1998, pp. 244-250
Authors:
FRACKIEWICZ EJ
SRAMEK JJ
HERRERA JM
KURTZ NM
CUTLER NR
Citation: Ej. Frackiewicz et al., ETHNICITY AND ANTIPSYCHOTIC RESPONSE, The Annals of pharmacotherapy, 31(11), 1997, pp. 1360-1369
Authors:
SRAMEK JJ
MACK RJ
AWNI W
HOURANI J
JHEE SS
BARTO S
CUTLER NR
Citation: Jj. Sramek et al., 2 RAPID-DOSE TITRATIONS OF SERTINDOLE IN PATIENTS WITH SCHIZOPHRENIA, Journal of clinical psychopharmacology, 17(5), 1997, pp. 419-422
Authors:
SRAMEK JJ
FRACKIEWICZ EJ
CUTLER NR
Citation: Jj. Sramek et al., EFFICACY AND SAFETY OF 2 DOSING REGIMENS OF BUSPIRONE IN THE TREATMENT OF OUTPATIENTS WITH PERSISTENT ANXIETY, Clinical therapeutics, 19(3), 1997, pp. 498-506
Authors:
CUTLER NR
SRAMEK JJ
GREENBLATT DJ
CHAIKIN P
FORD N
LESKO LJ
DAVIS B
WILLIAMS RL
Citation: Nr. Cutler et al., DEFINING THE MAXIMUM TOLERATED DOSE - INVESTIGATOR, ACADEMIC, INDUSTRY AND REGULATORY PERSPECTIVES, Journal of clinical pharmacology, 37(9), 1997, pp. 767-783
Authors:
CUTLER NR
VINCENT J
JHEE SS
TENG RL
WARDLE T
LUCAS G
DOGOLO LC
SRAMEK JJ
Citation: Nr. Cutler et al., PENETRATION OF TROVAFLOXACIN INTO CEREBROSPINAL-FLUID IN HUMANS FOLLOWING INTRAVENOUS-INFUSION OF ALATROFLOXACIN, Antimicrobial agents and chemotherapy, 41(6), 1997, pp. 1298-1300
Authors:
CUTLER NR
SALAZAR DE
JHEE SS
SRAMEK JJ
Citation: Nr. Cutler et al., MONITORING OF ACUTE MIGRAINE ATTACKS - PLACEBO-RESPONSE AND SAFETY DATA, Neurology, 48(3), 1997, pp. 1138-1138
Authors:
SRAMEK JJ
FORREST M
MENGEL H
JHEE SS
HOURANI J
CUTLER NR
Citation: Jj. Sramek et al., A BRIDGING STUDY OF LU-25-109 IN PATIENTS WITH PROBABLE ALZHEIMERS-DISEASE, Life sciences, 62(3), 1997, pp. 195-202
Authors:
SRAMEK JJ
ANAND R
HARTMAN R
CUTLER NR
Citation: Jj. Sramek et al., A BIOEQUIVALENCE STUDY OF GENERIC AND BRAND CLOZAPINE IN SCHIZOPHRENIC-PATIENTS, Clinical pharmacology and therapeutics, 61(2), 1997, pp. 90-90
Authors:
PIERCY MA
SRAMEK JJ
KURTZ NM
CUTLER NR
Citation: Ma. Piercy et al., PLACEBO-RESPONSE IN ANXIETY DISORDERS, The Annals of pharmacotherapy, 30(9), 1996, pp. 1013-1019
Authors:
CUTLER NR
SRAMEK JJ
LUNA A
MENA I
BRASS EP
KURTZ NM
BRENNAN JJ
Citation: Nr. Cutler et al., EFFECT OF THE ACE-INHIBITOR CERONAPRIL ON CEREBRAL BLOOD-FLOW IN HYPERTENSIVE PATIENTS, The Annals of pharmacotherapy, 30(6), 1996, pp. 578-582
Authors:
SHROTRIYA RC
CUTLER NR
SRAMEK JJ
VEROFF AE
HIRONAKA DY
Citation: Rc. Shrotriya et al., EFFICACY AND SAFETY OF BMY-21,502 IN ALZHEIMER-DISEASE, The Annals of pharmacotherapy, 30(12), 1996, pp. 1376-1380
Authors:
CUTLER NR
SRAMEK JJ
KILBORN JR
Citation: Nr. Cutler et al., THE BRIDGING CONCEPT - OPTIMIZING DOSE FOR PHASE II III IN ALZHEIMERS-DISEASE/, Neurodegeneration, 5(4), 1996, pp. 511-514